Envoy Medical reports Q3 EPS (37c) vs. 13c last year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2024
0mins
Q3 Revenue Decline: Envoy Medical reported a Q3 revenue of $56,000, down from $80,000 the previous year, while highlighting significant advancements in their fully implanted hearing devices.
Regulatory and Reimbursement Progress: The company received FDA approval for a pivotal trial of the Acclaim cochlear implant and is making strides in securing reimbursement for the Esteem device, alongside support for legislative changes regarding device classification.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COCH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COCH
About COCH
Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Envoy Medical to Participate in Small Cap Growth Investor Conference
- Conference Participation Announcement: Envoy Medical has announced its participation in the Small Cap Growth Virtual Investor Conference on February 5, 2026, showcasing its innovative technologies in hearing health, which is expected to attract investor interest and enhance the company's visibility.
- Schedule Details: The conference is set for 10:00 A.M. ET, during which management will present and answer real-time questions from investors, aiming to enhance engagement and transparency with stakeholders.
- Technology Innovation Showcase: Envoy Medical focuses on providing innovative hearing solutions, with its Esteem® active middle ear implant commercially available in the U.S. since 2010, demonstrating the company's leadership in the hearing loss sector.
- Product Development Progress: The company is also developing the Acclaim® cochlear implant, which, although currently an investigational device, holds significant market potential that could further drive the company's strategic positioning in the hearing health industry.
Continue Reading
Envoy Medical to Participate in Small Cap Growth Investor Conference
- Conference Participation: Envoy Medical will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026, showcasing its innovative hearing health technologies, which is expected to attract investor interest and enhance the company's visibility.
- Q&A Session: Following the presentation, a real-time Q&A session will allow investors to submit questions, enhancing interactivity and further deepening investor understanding and trust in the company's products.
- Product Overview: Envoy Medical focuses on providing innovative hearing solutions, with its Esteem® active middle ear implant commercially available in the U.S. since 2010, while the Acclaim® cochlear implant remains investigational, highlighting the company's cutting-edge position in hearing technology.
- Investor Relations: The company encourages investors to schedule one-on-one meetings with the management team via email, further strengthening communication and enhancing transparency and trust with investors.
Continue Reading